tbuckley/cabot-search huggingface dataset:
A 'supersalivation syndrome'
Authors: A. J. Miller
Journal: JAMA (1984)

<h3>In Reply.—</h3> As a family physician and family practice educator, I have no quarrel with Dr McMillen's assessment of medical care in the "real world" and, in fact, share his enjoyment of office and community hospital medical practice. Both he and Dr Davidson<sup>1</sup>have taken my letter as a criticism of the competence and viability of the primary care internist when it was intended as a commentary on the "traditional academic perspective." Although I trained in family practice, a good deal of my time was spent in contact with internal medicine residents, practitioners, and faculty. In this academic setting, residents aspired to the knowledge, skills, and roles of their faculty mentors—academic subspecialty internists who themselves pursued the goal of becoming Dr Petersdorf's<sup>2</sup>"triple threat" academicians. Although often acknowledged as good physicians and sometimes as astute clinicians, practitioners of general internal medicine were not the role models for these residents.
Effects of ethanol on prostanoid production by liver fat-storing cells
Authors: R Flisiak
Journal: Hepatology (1993)

Fat-storing cells participate in the development of alcoholic liver disease. To study possible effects of ethanol on prostaglandin metabolism by fat-storing cells, we isolated them from normal rat liver. Cultured fat-storing cells produced substantial amounts (DNA, about 2 ng/μg every 24 hr) of prostaglandin E2 and prostaglandin I2 (measured as 6-keto prostaglandin F1α) but no significant amounts of prostaglandin F2α. This production was markedly enhanced by the addition of ethanol in concentrations likely to occur in the blood during alcohol consumption. We confirmed the presence of class 1 alcohol dehydrogenase activity and isoenzymes in the cytosol of cultured fat-storing cells in their second passage. The stimulatory effect of ethanol was inhibited by 4-methylpyrazole (an alcohol dehydrogenase inhibitor), exaggerated by disulfiram (an aldehyde dehydrogenase inhibitor) and reproduced by concentrations of acetaldehyde likely to occur in the liver. Thus, our results indicate that fat-storing cells produce vasodilatory prostaglandins and that this production is enhanced by the acetaldehyde that results from the oxidation of ethanol catalized by alcohol dehydrogenase present in these cells. (HEPATOLOGY 1993;18:153–159).
Excessive Zinc Ingestion
Authors: E. Randolph Broun
Journal: JAMA (1990)

Two patients with sideroblastic anemia secondary to zinc-induced copper deficiency absorbed excess zinc secondary to oral ingestion. The source of excess zinc was a zinc supplement in one case; in the other, ingested coins. In each case, the sideroblastic anemia was corrected promptly after removal of the source of excess zinc. These two cases emphasize the importance of recognizing this clinical entity, since the myelodysplastic features are completely reversible. (<i>JAMA</i>. 1990;264:1441-1443)
Abstract 2656: Regulation of HIF-1a by MDM2 in prostate cancer cells
Authors: Saad Ebrahim Alobid, Appu Rathinavelu
Journal: Cancer Research (2019)

Abstract MDM2 is an oncogene amplified in approximately 40% of all human prostate carcinomas, and such amplification is correlated very well with aggressive tumor phenotype, distant metastasis, poor treatment outcomes and overall increase in mortality. Interestingly, in cancer cells, hypoxia inducible factor-1alpha (HIF-1α) is activated to facilitate adaptation to the non-conducive tumor microenvironment, through the regulation of downstream genes to ensure tumor survival and progression through modification of protective biological processes. Our previous investigations have outlined a significant role for MDM2 overexpression in regulating HIF-1α under both normoxic and hypoxic conditions in MDM2 expressing LNCaP and MDM2 transfected LNCaP-MST cells, leading to angiogenesis and other detrimental effects. Therefore, our study was aimed to identify how HIF-1α level is regulated in these prostate cancer cells, as a result of MDM2 overexpression, under both normoxic and hypoxic conditions. Analysis of mRNA levels exhibited a significant transcriptional upregulation of HIF-1α in LNCaP-MST compared to LNCaP cells under normoxic condition. Interestingly, targeting the transcriptional machinery with Actinomycin D resulted in a significant downregulation of HIF-1α protein levels also under normoxic conditions. On the other hand, inhibition of proteasomal degradation with MG-132 resulted in further elevation of HIF-1α protein levels in normoxic condition. However, under hypoxic condition, the levels of HIF-1α mRNA seem to be unchanged in both cell lines. In support of these findings, LNCaP-MST cells exhibited a significant downregulation of VHL (Von Hippel-Lindau) levels compared to LNCaP cells under hypoxic condition. The VHL protein typically facilitates polyubiquitination of HIF1α that are marked for proteasomal degradation subsequent to prolyl hydroxylation. So far, our results have confirmed a positive correlation between MDM2 expression and HIF-1α levels under normoxic conditions, while protein degradation may play a significant role during hypoxic conditions. In conclusion, our study provides new evidences that are linking MDM2 overexpression to HIF-1α protein levels in prostate cancer cells under both normoxic and hypoxic conditions, which may be important while considering targeted therapies. (The financial support from the Royal Dames of Cancer Research Inc., Ft. Lauderdale, Florida is gratefully acknowledged). Citation Format: Saad Ebrahim Alobid, Appu Rathinavelu. Regulation of HIF-1a by MDM2 in prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2656.
NUTRITION AND BEHAVIOR
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Omitted Middle Initial in Byline
Journal: JAMA Pediatrics (2015)

Margreet W. Harskamp-van Ginkel, MD; Kevin D. Hill, MD; Kristian C. Becker, BA; Daniela Testoni, MD, MHS; Michael Cohen-Wolkowiez, MD, PhD; Daniel Gonzalez, PharmD, PhD; Jeffrey S. Barrett, PhD; Daniel K. Benjamin Jr, MD, PhD, MPH; David A. Siegel, MD; Patricia Banks, BS; Kevin M. Watt, MD; for the Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee
Penicillin reactions among patients in venereal disease clinics. A national survey
Authors: A. H. Rudolph
Journal: JAMA (1973)

To determine the nature, incidence, and trend of penicillin reactions among patients in veneral disease clinics, four cooperative surveys were conducted at five-year intervals. In the 1969 survey, 6.6% of 36,048 patients questioned claimed sensitivity to penicillin. Of 27,673 patients treated with penicillin, 0.66% experienced a penicillin reaction, the most frequent allergic reaction being urticaria. The incidence of anaphylaxis was 0.04%. During the four survey periods, one death occurred in 94,655 patients treated with penicillin. Since 1959, the incidence of penicillin reactions among venereal disease clinic patients has decreased.
INDUSTRIAL POLLUTION OF HUMAN ENVIRONMENT
Journal: JAMA (1949)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cryoimmunotherapy.
Authors: R J Ablin
Journal: BMJ (1972)

motor end plates of the lower portion of the face where the injury was situated the concentration of the toxin could have been high enough to produce palsy.The other possibility would be for the toxin to ascend up the nerve fibres in high enough concen- tration to paralyse the motor end plates while some toxin could be absorbed via the blood stream to reach the C.N.S., and give rise to genealized excitatory features.Whatever the explanation, facial palsy as a complication of tetanus is a rare occurrence.An intriguing aspect of the case was that the forehead had escaped while the lower portion of the face (including the orbicularis oculi) was affected.-Weare, etc.,
Correction: Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polyps
Authors: Marietta Iacucci, Cristina Trovato, Marco Daperno, Oluseyi Akinola, David Greenwald, Seth Gross, Arthur Hoffman, Jeffrey Lee, Brendan Lethebe, Mark Lowerison, Jennifer Nayor, Helmut Neumann, Timo Rath, Silvia Sanduleanu, Prateek Sharma, Ralf Kiesslich, Subrata Ghosh, John Saltzman
Journal: Endoscopy (2018)

Correction to:Development and validation of the SIMPLE endoscopic classification of diminutive and small colorectal polypsEndoscopy 2018; 50(08): 779-789DOI: 10.1055/s-0044-100791
Can Hospital Transfusion Committees Change Transfusion Practice?
Authors: Francesco Torella, Sarah L Haynes, Joanne Bennett, Darreul Sewell, Charles N Mccollum
Journal: Journal of the Royal Society of Medicine (2002)

Blood and blood products are commonly over-used in hospital practice. We investigated whether the introduction of a red-cell transfusion trigger (haemoglobin &lt;8 g dL –1 ) influenced transfusion practice in surgery. Coronary artery bypass grafts (CABGs, n=400), total hip replacements (n=107), colectomies (n=85) and transurethral prostatectomies (TURPs, n=158) were reviewed over two periods of six months, before and after the introduction of the policy by the local hospital transfusion committee. After introduction of the policy, the proportion of patients transfused fell from 57% to 45% with CABGs (P=0.02) and from 52% to 26% with hip replacements (P=0.006); for colectomies and TURPs there was no change. Hospital stay did not increase in any of the groups. In the second period, haemoglobin concentration on discharge was lower after total hip replacement, by a mean (95% CI) of 0.7 (0.3–1.2) g dL –1 (P=0.002) and after colectomy, by a mean of 0.6 (0.1–1.1) g dL –1 (P=0.03). Although other factors cannot be excluded, we suggest that the reductions in red-cell transfusion were in large part attributable to the new transfusion policy.
The premenstrual syndrome. New views
Authors: D. R. Rubinow
Journal: JAMA (1992)

<h3>CASE PRESENTATION</h3> A 30-year-old married mother of four was referred to the National Institute of Mental Health for a cyclic mood disorder. She observed that over the preceding 7 years she experienced mood and somatic symptoms seemingly related to her menstrual cycle. Approximately 9 days before her menses, she would become sad and cry, want to be alone, and experience sensitivity to rejection, guilt, self-criticism, and occasional suicidal ideation. These symptoms were not responsive to expressed concern from others. Rather, she attempted to isolate herself because she became profoundly irritable around others and demonstrated anger, impatience, "meanness," overreactivity, and verbal outbursts. Her verbal loss of control caused problems at work and in her relationships with her family. Other symptoms included a decrease in her general level of interest and energy, an inability to initiate activities or to experience pleasure, fatigue, disturbed sleep, distractibility, indecisiveness, and increased appetite and food intake
The ultimate audit
Authors: R. W. Christie
Journal: JAMA (1985)

<h3>To the Editor.—</h3> I dreamed about my son Richard Mull last night and woke up crying. It has been seven years since he entered a boxing ring at West Point for his first graded bout, came out apparently uninjured to learn he had flunked the bout, and was left alone apparently because he did not feel well enough to return to the locker room. Someone found him a short time later. He was quickly slipping into the coma from which he never returned. It was his 19th birthday. Today, I read a newspaper article summarizing your editorial. A few moments later the publication itself appeared in my employer's in-box. If there is any way I can add my voice to that of yours and others who wish to end the brutal "sport" of boxing in this country, please feel free to call on me. A few years ago I put
History, Hospital
Authors: Harriet S. Meyer
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
Authors: Andrea Wang-Gillam, A. Craig Lockhart, Benjamin R. Tan, Rama Suresh, Kian-Huat Lim, Lee Ratner, Ashley Morton, Jess Huffman, Samantha Marquez, Nicolas Boice, David G DeNardo
Journal: Journal of Clinical Oncology (2018)

380 Background: Focal adhesion kinase (FAK) is consistently hyperactivated in multiple tumor types including pancreatic ductal adenocarcinoma (PDAC). Our preclinical work showed that FAK and PD-1 inhibitors elicit significant tumor regression, and a maximal response is achieved by combining FAK and PD-1 inhibitors with gemcitabine, suggesting the need for a cytotoxic agent to bolster antigen presentation (Jiang H et al, Nature Medicine 2016). Defactinib is an orally available, well-tolerated, potent ATP-competitive FAK inhibitor. Methods: Eligible patients are being treated according to the dose escalation schema (Table 1). A 3+3 design is being used. The study has an expansion portion for PDAC patients at the recommended phase 2 dose (RP2D). The primary endpoint is to determine the RP2D. Secondary endpoints include safety, toxicity, objective response rate, progression-free survival and overall survival. The exploratory endpoints include developing a molecular and immune profile for treatment response. Results: The dose escalation cohort has been completed with a total of 17 patients with refractory solid tumors being enrolled. The common treatment-related adverse events included fatigue (35%), nausea (29%), myalgia (29%), vomiting (24%), anorexia (24%), pruritus (24%) and fever (18%). No DLTs were observed, therefore the Level 5 dose was deemed to be the RP2D. Among the 13 patients evaluable for treatment response, 7 (54%) have stable disease. No partial or complete responses were observed to date. The median time on treatment was 127 days for all evaluable patients, and 104 days in the 6 PDAC patients with the longest time on treatment being 290 days. Paired biopsies in PDAC patients showed decreased p-FAK and changes in T cells infiltration and proliferation with treatment. Conclusions: The combination regimen is well tolerated. Dose Level 5 is the RP2D dose. The expansion cohort (PDAC only) is ongoing. Efficacy and correlative data is forthcoming. Dose LevelDefactinib D1-21 (BID)Pembrolizumab Gemcitabine (D1 and 8) Level 1 200 mg 200 mg- Level 2 400 mg 200 mg- Level 3 400 mg 200 mg 500 mg/m2 Level 4 400 mg 200 mg 750 mg/m2 Level 5 400 mg 200 mg 1,000 mg/m2 Clinical trial information: NCT02546531.
Experimental Research on Effect of High-Pressure Oxygen Therapy After Ligature of Hepatic Artery
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PROFESSIONAL TESTIMONIALS [?]
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiac Lesions Induced by Chemicals
Authors: T. Balazs, V. J. Ferrans
Journal: Environmental Health Perspectives (1978)

Chemically induced cardiomyopathies are frequently the consequences of a cardiac metabolic imbalance brought about by exaggerated functional affects. The infarctlike lesions induced by adrenergic beta-receptor stimulants and the vasodilating antihypertensives serve as examples of this phenomenon. Direct cardiotoxic mechanisms not related to cardiovascular functional effects are responsible for another class of toxic cardiomyopathy. An example of this is the cardiomyopathy produced by the anthracycline antineoplastic agents. The pathogenesis, morphological changes and toxicologic features of these cardiomyopathies are described with particular reference to their detection in preclinical toxicity studies.
BELGIUM
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal